Menu
GWAS Study

Chromosome 2q31.1 associates with ESRD in women with type 1 diabetes.

Sandholm N, McKnight AJ, Salem RM et al.

24029427 PubMed ID
GWAS Study Type
5081 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

SN
Sandholm N
MA
McKnight AJ
SR
Salem RM
BE
Brennan EP
FC
Forsblom C
HV
Harjutsalo V
MV
Mäkinen VP
MG
McKay GJ
SD
Sadlier DM
WW
Williams WW
MF
Martin F
PN
Panduru NM
TL
Tarnow L
TJ
Tuomilehto J
TK
Tryggvason K
ZG
Zerbini G
CM
Comeau ME
LC
Langefeld CD
GC
Godson C
HJ
Hirschhorn JN
MA
Maxwell AP
FJ
Florez JC
GP
Groop PH
Chapter II

Abstract

Summary of the research findings

Sex and genetic variation influence the risk of developing diabetic nephropathy and ESRD in patients with type 1 diabetes. We performed a genome-wide association study in a cohort of 3652 patients from the Finnish Diabetic Nephropathy (FinnDiane) Study with type 1 diabetes to determine whether sex-specific genetic risk factors for ESRD exist. A common variant, rs4972593 on chromosome 2q31.1, was associated with ESRD in women (P<5×10(-8)) but not in men (P=0.77). This association was replicated in the meta-analysis of three independent type 1 diabetes cohorts (P=0.02) and remained significant for women (P<5×10(-8); odds ratio, 1.81 [95% confidence interval, 1.47 to 2.24]) upon combined meta-analysis of the discovery and replication cohorts. rs4972593 is located between the genes that code for the Sp3 transcription factor, which interacts directly with estrogen receptor α and regulates the expression of genes linked to glomerular function and the pathogenesis of nephropathy, and the CDCA7 transcription factor, which regulates cell proliferation. Further examination revealed potential transcription factor-binding sites within rs4972593 and predicted eight estrogen-responsive elements within 5 kb of this locus. Moreover, we found sex-specific differences in the glomerular expression levels of SP3 (P=0.004). Overall, these results suggest that rs4972593 is a sex-specific genetic variant associated with ESRD in patients with type 1 diabetes and may underlie the sex-specific protection against ESRD.

258 European ancestry female cases, 935 European ancestry female controls, 387 European ancestry male cases, 655 European ancestry male controls

Chapter III

Study Statistics

Key metrics and study information

5081
Total Participants
GWAS
Study Type
Yes
Replicated
178 European ancestry female cases, 594 European ancestry female controls, 251 European ancestry male cases, 494 European ancestry male controls, 252 female cases, 479 female controls, 256 male cases, 342 male controls
Replication Participants
European
Ancestry
Finland, Italy, U.K., U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.